FDA VRBPAC Recommends JN.1 Boosters Despite Zero Prevalence

LP.8.1 Emerges Dominant from JN.1 Lineage but with Strong Immune Evasion

Jun 01, 2025

∙ Paid

Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

The COVID-19 vaccine campaign stumbles into its fifth year with a decision on fall boosters for a JN.1 lineage that is now extinct. The FDA VRBPAC panel is betting that the now dominant LP.8.1 a JN.1 progenitor will still respond to the historically ineffective vaccines.

Continue reading this post for free, courtesy of Peter A. McCullough, MD, MPH.

Or purchase a paid subscription.